Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. RUA Life Sciences's Revenue for the
six
months ended in Mar. 2026 was £2.75 Mil. RUA Life Sciences's Total Assets for the quarter that ended in Mar. 2026 was £8.93 Mil. Therefore, RUA Life Sciences's Asset Turnover for the quarter that ended in Mar. 2026 was 0.31.
Asset Turnover is linked to ROE % through Du Pont Formula. RUA Life Sciences's annualizedROE % for the quarter that ended in Mar. 2026 was -5.62%. It is also linked to ROA % through Du Pont Formula. RUA Life Sciences's annualizedROA % for the quarter that ended in Mar. 2026 was -4.50%.
RUA Life Sciences (LSE:RUA) Asset Turnover Explanation
Asset Turnover is linked to ROE % through Du Pont Formula.
RUA Life Sciences's annulizedROE % for the quarter that ended in Mar. 2026 is
Note:
The Net Income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
RUA Life Sciences's annulizedROA % for the quarter that ended in Mar. 2026 is
Note:
The Net Income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
RUA Life Sciences Asset Turnover Related Terms
RUA Life Sciences Asset Turnover Historical Data
* Premium members only.
The historical data trend for RUA Life Sciences's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:RUA vs ABT, SYK, MDT: Asset Turnover Comparison
For the Medical Devices subindustry, RUA Life Sciences's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RUA Life Sciences Asset Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's Asset Turnover distribution charts can be found below:
* The bar in red indicates where RUA Life Sciences's Asset Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
RUA Life Sciences (LSE:RUA) has a Asset Turnover of 0.31 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on RUA Life Sciences and its competitors.
Is RUA Life Sciences' Asset Turnover too high?
RUA Life Sciences' current Asset Turnover is 0.31. Overall, RUA Life Sciences has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RUA Life Sciences' Asset Turnover compare to ABT and SYK?
RUA Life Sciences' Asset Turnover of 0.31 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Medical Devices & Instruments company?
A good Asset Turnover depends on the Medical Devices & Instruments industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on RUA Life Sciences and its competitors. RUA Life Sciences's current Asset Turnover is 0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RUA Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RUA Life Sciences (LSE:RUA) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.17, compared to a current price of £0.24 — trading 41.2% above its estimated fair value. The current Asset Turnover is 0.31. RUA Life Sciences' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For RUA Life Sciences (LSE:RUA), the current Asset Turnover is 0.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RUA Life Sciences (LSE:RUA) Overvalued in 2026?
Based on GuruFocus' analysis, RUA Life Sciences stock appears to be overvalued.
The current stock price of £0.24 is trading 41.2% above its estimated GF Value™ of £0.17.
GuruFocus considers RUA Life Sciences to be Significantly Overvalued.
Key valuation signals for LSE:RUA:
Asset Turnover: 0.31
GF Value™: £0.17 vs. price of £0.24 (41.2% above fair value)
No single metric tells the full story. See the LSE:RUA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
47GF Score
Get the complete analysis for LSE:RUA
Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:RUA has been successfully added to your 
